| scholarly article | Q13442814 |
| P50 | author | Michael T Lotze | Q89121415 |
| Steven Rosenberg | Q2347448 | ||
| P2093 | author name string | Robb RJ | |
| Sharrow SO | |||
| Frana LW | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 157-166 | |
| P577 | publication date | 1985-01-01 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. | |
| P478 | volume | 134 |
| Q49332278 | A Case of Myocarditis and Near-Lethal Arrhythmia Associated With Interleukin-2 Therapy |
| Q40779138 | A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma |
| Q38658719 | Administration of recombinant IL-2 augments the level of serum IgM in an IL-2 deficient patient |
| Q58058307 | An assessment of the effects of swainsonine on survival of mice injected with B16-F10 melanoma cells |
| Q39832526 | An update on human interleukin-1: from molecular biology to clinical relevance |
| Q37470571 | Anterior pituitary hormone control by interleukin 2 |
| Q35163167 | Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety |
| Q39152916 | Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date |
| Q70362835 | Apparent interleukin 2 (IL-2) inhibitory activity of human serum is due to rapid killing of IL-2-dependent mouse cells |
| Q36370697 | Basophils are the major producers of IL-4 during primary helminth infection |
| Q89474618 | Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy |
| Q41657844 | Bispecific Antibody-directed Antitumor Activity of Human CD4+Helper/Killer T Cells Induced by Anti-CD3 Monoclonal Antibody plus Interleukin 2 |
| Q33811204 | Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy |
| Q54421785 | Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2. |
| Q47774017 | Characterization of Interleukin-2 (IL-2) receptor expression and action of IL-2 and IL-6 on normal anterior pituitary cell growth |
| Q42585683 | Clinical and immunological effects of single bolus administration of recombinant interleukin-2 in cattle. |
| Q68485520 | Decreased activity of interleukin-2 inhibitor in plasma of patients with systemic lupus erythematosus |
| Q69688427 | Decreased interleukin 2 inhibitor in sera of patients with autoimmune disorders |
| Q45833763 | Effect of recombinant human interleukin 2 on the growth of a BALB/c sarcoma induced by Moloney murine sarcoma virus |
| Q55258552 | Effects of PSK on interleukin-2 production by peripheral lymphocytes of patients with advanced ovarian carcinoma during chemotherapy. |
| Q36989234 | Effects of human interleukin-1 on natural killer cell activity: is fever a host defense mechanism for tumor killing? |
| Q68095000 | Effects of recombinant interleukin 2 on immunological effector cells of the peripheral blood in patients with HBe antigen-positive chronic hepatitis |
| Q69994900 | Effects of systemic in vivo interleukin-2 (IL-2) reconstitution in patients with acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC) on phenotypes and functions of peripheral blood mononuclear cells (PBMC) |
| Q50910156 | Eosinophil differentiating activity in sera of patients with AIDS under recombinant IL-2 substitution. |
| Q38745962 | Gene therapy: a potential approach for cancer pain |
| Q72374056 | Generation of tumor-specific cytotoxic T lymphocytes in vivo by combined treatment with inactivated tumor cells and recombinant interleukin-2 |
| Q70823131 | High-dose continuous venous infusion of interleukin-2: influence of dose and infusion rate on tumoricidal function and lymphocyte subsets |
| Q41706967 | High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. |
| Q33561339 | Hormones and the immune response |
| Q57038233 | IL-2/CD25: A Long-Acting Fusion Protein That Promotes Immune Tolerance by Selectively Targeting the IL-2 Receptor on Regulatory T Cells |
| Q34423519 | IL-2: the first effective immunotherapy for human cancer. |
| Q24531350 | Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection |
| Q56767477 | Immunoendocrine aspects of major depression |
| Q40783088 | Immunologic effects on peripheral lymphoid cells from patients with chronic hepatitis type B during administration of recombinant interleukin 2. |
| Q55362851 | Immunotherapies: Exploiting the Immune System for Cancer Treatment. |
| Q70462807 | Immunotherapy with intralesional and systemic interleukin-2 of patients with non-small-cell lung cancer |
| Q68802117 | In vivo augmentation of the cytotoxicity of spleen lymphocytes against syngeneic B-16 melanoma cells and the suppression of the artificial metastases in C57BL/6 mice by subcutaneous multiple injections of high dose human recombinant interleukin-2 (r |
| Q48015339 | Increased plasma levels of soluble IL-2R are associated with severe Plasmodium falciparum malaria. |
| Q36081509 | Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2 |
| Q44685679 | Interleukin 2-activated killer cells: generation in collaboration with interferon gamma and its suppression in cancer patients |
| Q24564695 | Interleukin-2 and interleukin-2 receptor expression in human corticotrophic adenoma and murine pituitary cell cultures |
| Q44055805 | Interleukin-2 can induce suppression of human natural killer cell cytotoxicity |
| Q37822364 | Interleukin-2 therapy for human cancer |
| Q44165330 | Interleukin-2-dependent control of disease development in spontaneously diabetic BB rats |
| Q45888906 | Intralymphatic interleukin-2 treatment of a hemophiliac AIDS patient with defective interleukin-2 production |
| Q38694439 | Lymphokine activated killer cells |
| Q36530484 | Motility and ultrastructure of large granular lymphocytes on lipid bilayers reconstituted with adhesion receptors LFA-1, ICAM-1, and two isoforms of LFA-3 |
| Q36305283 | Procalcitonin, MR-Proadrenomedullin, and Cytokines Measurement in Sepsis Diagnosis: Advantages from Test Combination |
| Q34565648 | Production of and in vitro response to interleukin 2 in the acquired immunodeficiency syndrome |
| Q42483263 | Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: I. Phenotypic and functional analysis of the peripheral blood mononuclear cells |
| Q37137406 | Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation |
| Q69738244 | Severe intrahepatic cholestasis in patients treated with recombinant interleukin-2 and lymphokine-activated killer cells |
| Q30437950 | Stoichiometry based steady-state hepatic flux analysis: computational and experimental aspects |
| Q68814315 | Suppression of pulmonary tumour metastasis in mice by recombinant human interleukin-2: role of asialo GM1-positive cells |
| Q72873376 | Synergetic effect of interleukin-2 and cellular cytotoxicity against a novel tumor-associated carbohydrate antigen Le(a)/Le(a) (dimeric Le(a)) mediated by monoclonal antibody NCC-ST-421 in adoptive immunization using SCID mice |
| Q36302958 | Systemic immunological effects of cytokine genes injected into skeletal muscle |
| Q89457554 | TCB2, a new anti-human interleukin-2 antibody, facilitates heterodimeric IL-2 receptor signaling and improves anti-tumor immunity |
| Q68822512 | The anti-tumour efficacy of human recombinant interleukin 2. Correlation between sensitivity of tumours to the cytolytic effect of LAK cells in vitro and their susceptibility to interleukin 2 immunotherapy in vivo |
| Q35657649 | The clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatment |
| Q68809345 | The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2) |
| Q39512710 | The development of new immunotherapies for the treatment of cancer using interleukin-2. A review |
| Q38424758 | The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases |
| Q40762779 | Transcatheter arterial injection of autologous lymphokine-activated killer (LAK) cells into patients with liver cancers |
| Q68826682 | Transfer of spleen cells expanded by T cell growth factor suppresses arthritis induced in rats |
| Q69333914 | Treatment of hepatocellular carcinoma utilizing lymphokine-activated killer cells and interleukin-2 |
| Q26745898 | Until Death Do Us Part: Necrosis and Oxidation Promote the Tumor Microenvironment |
Search more.